Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

LABORATÓRIOS PFIZER LDA

NIF 500162166
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €56,458,056 135 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €56,458,056 135 contracts
A2 · Late Publication €29,829,874,558 6,772 contracts
Contract published to BASE more than 10 days after the signing date
LOW €29,829,874,558 6,772 contracts
A5 · Threshold Splitting €18,823,819 222 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €18,823,819 222 contracts
A6 · Low Competition €6,773,045 73 contracts
Only one bidder participated in a competitive procedure
MEDIUM €6,773,045 73 contracts
A9 · Price Overrun €21,333 5 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €21,333 5 contracts
A9 · Abnormal Price Reduction €36,629,926,533 3,688 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €36,629,926,533 3,688 contracts
B5 · Benford's Law Deviation €983,875,478 4 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €983,875,478 4 contracts
C3 · Missing Mandatory Fields €15,847,744 196 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €15,847,744 196 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

886
€4,993,899,452
624
€1,263,106,038
209
€1,227,738,395
212
€1,216,896,438
1,072
€1,149,909,681
143
€1,075,187,477
222
€1,072,329,340
73
€1,055,805,117
90
€1,047,815,411
291
€1,044,515,760
130
€1,043,365,206
80
€1,042,745,652
100
€1,034,016,470
62
€1,022,876,502
39
€1,012,980,395
387
€1,012,502,146
97
€997,109,581
507
€949,915,644
223
€926,252,911
310
€923,744,593
Page 1 of 5 · 81 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 5 · 222 contracts

261X000046 - ELRANATAMAB 76 MG/ 1,9 ML SOL INJ SC
PT · 13658851 · Contratação excluída II
A5 · Threshold Splitting
€149,897 2026-02-25
261Y000018 para 2026 - CPA 2025/1367 - Medicamentos do aparelho digestivo
PT · 13094424 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€144,301 2026-02-03
Aquisição de Estimulantes da Eritropoiese
PT · 13047755 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€143,170 2026-01-06
CPA 2023/492 - Medicamentos anti-infeciosos
PT · 13074998 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€19,760 2025-12-30
ADCM 4858/25 - Medicamentos Diversos
PT · 13511853 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,283 2025-11-14
Medicamentos
PT · 12127052 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,119 2025-11-06
41/188/2026 - Medic. do Aparelho locomotor. empregues na terapêutica das doenças endócrinas e hormonas
PT · 12688568 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,777 2025-11-06
Medicamentos
PT · 12065597 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,119 2025-11-06
ADCM 4591/25 - MEDICAMENTOS
PT · 12020341 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,983 2025-11-04
Q1/2318/2025 - AGREGAÇÃO URGENTE - MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 11976899 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,294,078 2025-10-22
AQUISIÇÃO DE VARIOS MEDICAMENTOS SPMS PARA 2025 -19- ULSLO
PT · 12722786 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€73,341 2025-10-21
ADCM 4407/25 - MEDICAMENTOS
PT · 0e1810b318f509e342b0 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€4,860 2025-10-17
IMUNOMODULADORES - INOTUZUMAB OZOGAMICINA
PT · 11781917 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,488 2025-10-10
251X000305 - ELRANATAMAB 76 MG/ 1,9 ML SOL INJ SC
PT · 11737726 · Contratação excluída II
A5 · Threshold Splitting
€149,897 2025-09-24
Medicamentos
PT · 11799534 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,889 2025-09-19
VACINAS
PT · 11757626 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€73,924 2025-09-19
Aquisição Vacina Pfizer
PT · 13711487 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,989 2025-09-03
AE/2084/2025 - NIRMATRELVIR+RITONAVIR (150+100MG)
PT · 11605534 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€143,292 2025-07-25
ADCM3064/25 - MEDICAMENTOS DIVERSOS
PT · 11616250 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€149,723 2025-07-11
CEFTAZIDIMA + AVIBACTAM (2000MG+500MG) - 1F/00548/25
PT · 11713538 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,001 2025-07-02
251X000204 - ELRANATAMAB 76 MG/ 1,9 ML SOL INJ SC
PT · 11543652 · Contratação excluída II
A5 · Threshold Splitting
€149,897 2025-06-30
Acordo Quadro para fornecimento de Medicamentos anti-infeciosos, na área da Saúde – CP 2023/492 – SPMS
PT · 11733275 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€71,952 2025-06-20
Acordo Quadro para fornecimento de Medicamentos anti-infeciosos, na área da Saúde – CP 2023/492 – SPMS
PT · 11733135 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€71,952 2025-06-20
RITLECITINIB 50 MG, abrigo do Programa Acesso Precoce PAPLITFULO
PT · 11542474 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,418 2025-06-17
Q1/2117/2025 – TOFACITINIB 5 MG COMP
PT · 11522687 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€4,959 2025-06-13
ADCM 2693/25 - MEDICAMENTOS DIVERSOS
PT · 11594025 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€147,567 2025-06-09
ADCM 1762/25 - MEDICAMENTOS DIVERSOS
PT · 11484429 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,912 2025-04-14
61/2740/2025 - Medicamento Sirolímus 1 mg/ml Sol oral Fr 60 ml
PT · 11370463 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,837 2025-04-10
VÁRIOS MEDICAMENTOS
PT · 11334584 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award
€19,853 2025-04-03
LORLAtinib 100 mg Comp
PT · 11370428 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,518 2025-03-03
ELRANATAMAB 40 MG/ML SOL INJ FR 1.9 ML SC
PT · 11751305 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€149,897 2025-02-28
MEDICAMENTOS
PT · 11313241 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,131 2025-02-21
Aquisição de Medicamentos do aparelho geniturinário (AQ2023495)
PT · 11261522 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€72,585 2025-02-20
MEDICAMENTOS EXCLUSIVOS LABORATORIOS PFIZER, LDA
PT · 11221002 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€142,773 2025-02-12
EXCL PFIZER
PT · 11238700 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,950 2025-02-10
040100702025-MEDICAMENTOS PARA A MÁQUINA DE REEMBALAGEM - PROUD
PT · 11226487 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,206 2025-01-24
VÁRIOS MEDICAMENTOS
PT · 11191927 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,862 2025-01-20
Medicamentos
PT · 11324997 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,849 2025-01-08
EXCL LAB PFIZER - TUCATINIB
PT · 11250876 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€146,966 2025-01-07
VÁRIOS MEDICAMENTOS
PT · 11219229 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€73,545 2024-12-23
1217/2024 - Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2021/055 (Medicamentos diversos), 2022/014 (Medicamentos do aparelho digestivo), 2022/019 (Medicamentos antipsicóticos, anestésicos e relaxantes musculares), 2022/055 (Medicamentos diversos), 2022/173 (Medicamentos diversos), 2023/304 (Medicamentos do grupo 4: sangue), 2023/305 (Medicamentos do aparelho cardiovascular), 2023/306 (Corretivos da volémia, soluções para conservação de órgãos, hemodiálise, hemofiltração e outras soluções estéreis), 2023/436 (Medicamentos para o sistema nervoso central), 2023/437 (Medicação antialérgica, vitaminas e sais minerais e medicamentos usados no tratamento de intoxicações), 2023/481 (Medicamentos diversos), 2023/490 (Medicamentos usados em afeções cutâneas), 2023/491 (Medicamentos do foro oncológico e imunomoduladores), 2023/492 (Medicamentos anti-infeciosos), 2023/671 (Medicamentos diversos), 2024/107 (Medicamentos diversos (II)), 2024/780 (Medicamentos do aparelho loc
PT · 11239205 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€149,266 2024-12-19
MEDICAMENTOS
PT · 7b0989e18b2501fe64f6 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,837 2024-12-11
MEDICAMENTOS
PT · 11140349 · Ajuste Direto Regime G...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€147,407 2024-12-10
050104172024 - C/ BASE CPA 2023_491- Inotuzumab ozogamicina 1 mg Pó conc sol inj Fr IV
PT · 11077122 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€143,070 2024-12-04
050103842024 C/ BASE NO CPA 2023_491
PT · 11029860 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,547 2024-11-15
241G001501 - NIRMATRELVIR 150 MG+RITONAVIR 100 MG COMP
PT · 10998219 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€72,000 2024-10-29
VÁRIOS MEDICAMENTOS
PT · 10962746 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,243 2024-10-08
VORIconazol; Hidrocortisona Act-O-Vial
PT · 10980138 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,828 2024-09-30
INOTUzumab ozogamicina
PT · 11009380 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,076 2024-09-27
VÁRIOS MEDICAMENTOS
PT · 10939039 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,555 2024-09-24
Next →
Overview
Total Value Won
€37,032,726,661
Contracts Won
9,615
Score 328155 · CRITICAL RISK
NIF
500162166
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.C. [P-f05d]
    Gerente
    since 2022-11-28
  • F.J. [P-b870]
    Gerente
    since 2025-02-27
  • P.A. [P-9563]
    Gerente
    since 2014-06-26
  • P.G. [P-1249]
    Gerente
    since 2008-04-22
  • R.J. [P-516e]
    Gerente
    since 2021-06-22
  • T.S. [P-c179]
    Gerente
    since 2021-06-22
  • P.W. [P-bd21]
    Sócio
    since 2012-08-13
  • P.W. [P-bd21]
    Sócio
    since 2012-08-30
  • P.S. [P-b820]
    Sócio
    since 2012-08-13
  • P.S. [P-b820]
    Sócio
    since 2012-08-30
  • A.P. [P-1479]
    Gerente
    2009-03-04 → 2016-10-06
  • A.P. [P-1479]
    Gerente
    until 2013-10-15
  • A.C. [P-f05d]
    Gerente
    2014-10-28 → 2021-06-22
  • A.P. [P-6d4c]
    Gerente
    2012-10-26 → 2014-11-24
  • B.G. [P-2ebe]
    Gerente
    2023-04-06 → 2025-12-02
  • C.M. [P-2e72]
    Gerente
    2014-06-26 → 2015-07-03
  • C.M. [P-2e72]
    Gerente
    2021-06-22 → 2022-11-28
  • F.J. [P-b870]
    Gerente
    2012-10-26 → 2014-06-26
  • L.R. [P-b234]
    Gerente
    2017-06-07 → 2019-01-24
  • L.F. [P-9705]
    Gerente
    2009-03-04 → 2012-09-24
  • M.D. [P-6765]
    Gerente
    2021-06-22 → 2023-04-06
  • M.M. [P-70e3]
    Gerente
    2009-03-04 → 2015-07-03
  • S.P. [P-a960]
    Gerente
    2019-02-07 → 2021-02-17
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned